B-Cell CLL/lymphoma 7A (BCL7A) Peptid
Kurzübersicht für B-Cell CLL/lymphoma 7A (BCL7A) Peptid (ABIN937090)
Target
Spezies
Quelle
Applikation
-
-
Protein-Typ
- Synthetic
-
Sequenz
- CGSEVTTPEN SSSPGMMDMH DDNSNQSSIA DASPIKQENS SNSSPAPEPN
-
Produktmerkmale
-
A synthetic peptide for use as a blocking control in assays to test for specificity of BCL7 A antibody,
Alternative Names: BCL7A control peptide, BCL7A antibody Blocking Peptide, Anti-BCL7A Blocking Peptide, B-Cell Cll/Lymphoma 7A Blocking Peptide, BCL7 Blocking Peptide, BCL7A, BCLA-7, BCLA 7, BCLA-7 Blocking Peptide, BCLA 7 Blocking Peptide
-
-
-
-
Applikationshinweise
- Optimal conditions should be determined by the investigator
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
-
Buffer
- PBS
-
Handhabung
- Avoid repeated freeze/thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- Store at -20 °C long term.
-
-
- BCL7A (B-Cell CLL/lymphoma 7A (BCL7A))
-
Hintergrund
- This gene is directly involved, with Myc and IgH, in a three-way gene translocation in a Burkitt lymphoma cell line. As a result of the gene translocation, the N-terminal region of the gene product is disrupted, which is thought to be related to the pathogenesis of a subset of high-grade B cell non-Hodgkin lymphoma. The N-terminal segment involved in the translocation includes the region that shares a strong sequence similarity with those of BCL7B and BCL7C. Two transcript variants encoding different isoforms have been found for this gene.
-
Molekulargewicht
- 25 kDa
Target
-